Cambridge, UK, 30 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
Completed Covid-19 Research Project Delivers Encouraging Results
Further to the announcement on 4 May 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
Braveheart Investment Group plc (AIM: BRH) announces its audited annual results for the financial year ended 31 March 2021, highlights of which are set out below:
Further to the announcements on 29 January 2021, Braveheart Investment Group plc (AIM: BRH), is pleased to provide an update concerning progress to develop a COVID-19 test that Paraytec Limited
In the interim results for the six months ended 30 September 2020, the board of Braveheart (the “Board”) announced that it had declared the payment of a special interim dividend
Braveheart announces that on 18 November 2020, it sold a total of 112,592,405 ordinary shares in Remote Monitored System plc (“RMS”).
Braveheart announces that on 16 and 17 November 2020, it sold a total of 287,400,000 ordinary shares in Remote Monitored System plc (“RMS”) at a weighted average price of approximately
Braveheart announces that on 6 November 2020 it exercised a total of 10 million options over ordinary shares in Remote Monitored Systems plc (“RMS”) at an exercise price of 0.5p
Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited (“P2F”) anti-viral surgical mask project.
Braveheart Investment Group (AIM: BRH), is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of
